Zentalis promotes Kevin Bunker to Chief Scientific Officer, steps down as COO

Zentalis Pharmaceuticals, Inc.

Kevin Bunker promoted to Chief Scientific Officer, effective September 26, 2022.
Bunker stepped down as Chief Operating Officer upon the promotion.
No replacement for COO role announced; internal organizational change.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Kevin Bunker

Chief Scientific Officer

ZNTL · Zentalis Pharmaceuticals, Inc.

Effective: 2022-09-26
Filed: September 27, 2022, 7:59 PM ET

On and effective September 26, 2022, Kevin Bunker was promoted to Chief Scientific Officer of Zentalis Pharmaceuticals, Inc. (the “Company”) and, as a result of his promotion, stepped down as Chief Operating Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Kevin Bunker changed role as Chief Scientific Officer at Zentalis Pharmaceuticals, Inc..

Action: promoted
Role: Chief Scientific Officer

Exact text from the filing

On and effective September 26, 2022, Kevin Bunker was promoted to Chief Scientific Officer of Zentalis Pharmaceuticals, Inc. (the “Company”) and, as a result of his promotion, stepped down as Chief Operating Officer of the Company.

View on SEC.gov

Zentalis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001725160-22-000170

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.